Drug Profile
Eflornithine oral - Orbus Therapeutics
Latest Information Update: 02 Jun 2023
Price :
$50
*
At a glance
- Originator Orbus Therapeutics
- Class Antihyperglycaemics; Antineoplastics; Basic amino acids; Diamino amino acids; Small molecules
- Mechanism of Action Ornithine decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Anaplastic astrocytoma
- Phase I Glioblastoma
Most Recent Events
- 26 May 2023 Phase-I clinical trials in Glioblastoma (First line therapy, Combination therapy) in USA (PO) (NCT05879367)
- 10 Jan 2023 Orbus Therapeutics in-licenses intellectual property covering methods of use of eflornithine in Bachmann-Bubb syndrome from Michigan State University and Helen DeVos Children’s Hospital
- 28 Sep 2022 Eflornithine oral is still in the phase III STELLAR trial for Anaplastic astrocytoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Belgium, Canada, France, Germany, Italy, Netherlands, United Kingdom (NCT02796261)